P
3.28
0.25 (8.09%)
| Penutupan Terdahulu | 3.03 |
| Buka | 3.05 |
| Jumlah Dagangan | 506,594 |
| Purata Dagangan (3B) | 1,051,561 |
| Modal Pasaran | 289,209,376 |
| Harga / Jualan (P/S) | 2.37 |
| Harga / Buku (P/B) | 1.48 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 May 2025 - 12 May 2025 |
| Margin Keuntungan | -96.06% |
| Margin Operasi (TTM) | -107.81% |
| EPS Cair (TTM) | -1.22 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -14.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 21.85% |
| Nisbah Semasa (MRQ) | 6.52 |
| Aliran Tunai Operasi (OCF TTM) | -45.15 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -24.16 M |
| Pulangan Atas Aset (ROA TTM) | -17.23% |
| Pulangan Atas Ekuiti (ROE TTM) | -48.91% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Menurun | Menurun |
| Diagnostics & Research (Global) | Menurun | Menurun | |
| Stok | Personalis, Inc. | Menurun | Menaik |
AISkor Stockmoo
-0.3
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | -0.25 |
|
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 31.33% |
| % Dimiliki oleh Institusi | 42.73% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Blue Water Life Science Advisors, Lp | 31 Dec 2024 | 1,132,900 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 8.00 (HC Wainwright & Co., 144.28%) | Beli |
| 8.00 (Craig-Hallum, 144.28%) | Beli | |
| Median | 8.00 (144.28%) | |
| Rendah | 7.00 (Needham, 113.74%) | Beli |
| Purata | 7.67 (134.20%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 3.66 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Needham | 10 Apr 2025 | 7.00 (113.74%) | Beli | 3.03 |
| 28 Feb 2025 | 7.00 (113.74%) | Beli | 4.14 | |
| Craig-Hallum | 17 Mar 2025 | 8.00 (144.27%) | Beli | 3.80 |
| HC Wainwright & Co. | 28 Feb 2025 | 8.00 (144.27%) | Beli | 4.14 |
| 27 Jan 2025 | 8.00 (144.27%) | Beli | 5.81 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 26 Mar 2025 | Pengumuman | Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference |
| 03 Mar 2025 | Pengumuman | New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection |
| 27 Feb 2025 | Pengumuman | Personalis Reports Fourth Quarter and Full Year 2024 Financial Results |
| 18 Feb 2025 | Pengumuman | Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference |
| 13 Feb 2025 | Pengumuman | Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results |
| 28 Jan 2025 | Pengumuman | Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |